David Baker
Chairman at DEVONIAN HEALTH GROUP INC.
Net worth: 18 $ as of 2024-04-29
Profile
Mr. David C.
Baker is a Non-Executive Chairman at Devonian Health Group, Inc. and a Chairman at Philadelphia Education Fund.
He is on the Board of Directors at Benchworks, Inc. and GRI Bio, Inc. Mr. Baker was previously employed as a President, Chief Executive Officer & Director by Vallon Pharmaceuticals, Inc., a President & Chief Executive Officer by Alcobra Ltd., and a Vice President-Commercial Strategy & New Business by Shire Pharmaceuticals, Inc. He received his undergraduate degree from Duke University and an MBA from The Fuqua School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GRI BIO, INC.
0.00% | 2023-12-30 | 42 ( 0.00% ) | 18 $ | 2024-04-29 |
| 2023-11-30 | 0 ( -.--% ) | - $ | 2024-04-29 |
David Baker active positions
| Companies | Position | Start |
|---|---|---|
| GRI BIO, INC. | Director/Board Member | - |
| DEVONIAN HEALTH GROUP INC. | Chairman | 2023-12-03 |
| Philadelphia Education Fund | Chairman | - |
Benchworks, Inc.
 Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Director/Board Member | - |
Former positions of David Baker
| Companies | Position | End |
|---|---|---|
| GRI BIOPAR | Chief Executive Officer | 2023-04-20 |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Chief Executive Officer | 2017-10-31 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 2013-11-30 |
Training of David Baker
| Duke University | Undergraduate Degree |
| The Fuqua School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| DEVONIAN HEALTH GROUP INC. | Health Technology |
| Private companies | 6 |
|---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
| Philadelphia Education Fund | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Commercial Services |
| GRI Bio, Inc. |
- Stock Market
- Insiders
- David Baker
